Skip to content
lifestyle.ribbon.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Legend Biotech USA Inc.
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
September 10, 2026
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
September 1, 2026
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
August 11, 2026
Legend Biotech Announces CEO Transition
July 27, 2026
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
June 2, 2026
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
June 1, 2026
Legend Biotech Announces Presentations at ASCO 2026
May 25, 2026
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
May 24, 2026
1
2
Next Page
→